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Erik J. Meijboom, MD, PhD, Utrecht, The Netherlands 
Renewed interest has arisen in the use of autologous 
tissue for both the reconstruction and construction of 
heart valves, to avoid the problems of calcification and 
primary tissue failure found with heterograft bioprosthe- 
ses and homograft valves. A method of intraoperative 
fabrication of an autologous tissue cardiac valve (ATCV) 
was described by Love and colleagues. 1 The kit used to 
construct he valve makes the assembly of the ATCV 
simple and straightforward. As recommended by the 
National Institutes of Health, in vivo testing showed 
excellent hemodynamic properties and no evidence of 
generalized calcification in the juvenile sheep model. In 
the clinical series, early follow-up results have also indi- 
cated good hemodynamic performance of the ATCV 
without regurgitation. On the basis of these encouraging 
results, the ATCV was used in a 4-year-old girl. This 
report describes the theoretic justification and advantages 
of using this valve in children. 
A 4-year-old girl, 16.2 kg in weight and 105 cm in 
height, was found to have coarctation of the aorta and 
aortic valve stenosis. When 3 years old, she underwent a
balloon dilatation of both lesions, which resulted in di- 
minished gradients across both the aortic valve and the 
coarctation (32 to 7 mm Hg and 15 to 7 mm Hg, 
respectively); however, an aortic insufficiency of 3/4 ap- 
peared. Because of increasing aortic insufficiency, residual 
stenosis, mitral insufficiency, and left ventricular hypertro- 
phy, the patient was then accepted for mitral valve plasty 
and aortic valve replacement. A mechanical valve would 
ordinarily have been preferred; after informed consent 
was obtained, however, an autologous valve was selected 
because of the absence of calcification in the sheep 
experiment. 
During operation, the native valve was found to be 
thickened and fibrosed, with the right cusp absent. After 
the leaflets were removed, a 14 mm Hegar dilatator could 
be introduced through the anulus. Once root enlargement 
was completed with Manougian and Seybold-Epting's 
technique, 2 the annular size was increased to allow im- 
plantation of a 19 mm Autogenics valve (Autogenics, 
Newbury Park, Calif.). Inspection of the mitral valve 
showed a prolapsed posterior leaflet, which was corrected 
by quandrangular resection. After declamping, sinus 
rhythm recurred and the patient was easily weaned from 
extracorporeal circulation. 
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The postoperative course was complicated by an airway 
infection that was treated successfully with antibiotics. 
Echocardiography revealed neither insufficiency nor re- 
sidual stenosis across the aortic or mitral valve (Doppler 
gradient of zero). On postoperative day 20, the patient 
was discharged. Follow-up after 2 months did not show 
any cardiac complaints, and echocardiographic results 
were unchanged. 
The intraoperative fabrication method of the ATCV, as 
described by Love and colleagues, 1 is shown in Fig. 1. The 
ATCV is constructed of autologous pericardium that has 
been cleaned of fatty tissue. The autologous pericardium 
is treated by brief immersion in a buffered 0.6% glutaral- 
dehyde solution. Once the patient's anulus has been sized, 
the valve is constructed while the sutures are placed in the 
anulus. 
Before implantation, the ATCV is tested. With the pro- 
vided Acceptance Test Device (Autogenics), the ATCV can 
be functionally examined. 4 This device allows the cycling of 
sterile saline solution through the valve with a closing 
pressure of 85 mm Hg; it also enables the surgeon to 
examine both the profile and the outflow end of the valve for 
prolapse, pinwheeling, and good coaptation. 
Making a heart valve prosthesis from the patient's own 
tissue is more appealing than using animal tissue. This is 
not a new idea; Senning began implanting autologous 
fascia lata valves in 1962. Senning's work inspired subse- 
quent trials with fascia lata valves by Ionescu 6 and Ed- 
wards 7 and with pericardium by Bj6rk and Hultquist. 8
These early experimental uses of autologous tissue were 
not successful because of problems with both the tissue 
and the methods used for construction. The fresh, un- 
treated tissue was subject to thickening and shrinkage, 
which led to early valve failure. When pericardium was 
treated with a 5-minute immersion in 0.6% glutaralde- 
hyde, the autologous tissue valves did not show thicken- 
ing, shrinkage, or generalized calcific degeneration after 5 
months in the juvenile sheep model. General tissue 
changes in bioprosthetic valves regularly occur after a 
couple of months in this model, whereas such changes 
take years to develop in human beings. Carpentier and 
associates 9 reported the absence of macroscopic calcifica- 
tion of the pericardium patches briefly immersed in 
glutaraldehyde used for mitral valve reconstruction i
young patients as long as 10 years after operation. More 
recently, Chauvaud and colleagues TM reported similar use 
of autologous pericardium as annular reinforcement in
cases of mitral valvuloplasty after 10-minute immersion in 
glutaraldehyde. Their group has seen no calcification of 
this tissue in patients as late as 10 years of follow-up. The 
ATCV is made simple and straightforward bythe use of a 
kit. The stent assembly has been cycled more than 800 
million times in the wear tester without failure. Labora- 
tory tests in animals indicate that the autologous valve 
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Fig. 1. A, Laying tissue on tissue-cutting die. 1, Tissue-cutting die; 2, preformed cutting blade; 3, pusher 
device. B, Assembled cutting device cutting tissue by pulling through pusher device. C, Wrapping tissue on 
inner stent, applying precut holes to buttons on stent. D, Lowering outer stent over inner stent, protecting 
buttons with cap. E, Removing protective cap from finished valve. 
may be more durable and resistant o calcification and 
degeneration than animal tissue valves, even in children. 
There is published evidence that the durability of hetero- 
graft valves may be a function of the residual immunoge- 
nicity of those valves after glutaraldehyde tanning of the 
tissue. 1~ 
A clinical trial in which 360 patients have been enrolled 
has been underway since 1992. There have been 21 deaths, 
none of which were attributed to failure of the Autogenics 
valve. On the basis of these encouraging results, we 
consider implantation of this valve in children to be 
justified. 
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